-
Cevostamab: Unveiling the Role of Anti-CD47 in Cancer Research(Post)
Quick Info Section: Key Facts About CevostamabWhat is Cevostamab?Cevostamab is an investigational monoclonal antibody targeting CD47, a cell surface protein that helps cancer cells evade
Tisotumab Vedotin: A Breakthrough in Targeted Cancer Therapy(Post)Quick Facts About Tisotumab VedotinWhat is Tisotumab Vedotin?Tisotumab Vedotin (Tivdak™) is an antibody-drug conjugate (ADC) designed to target tissue factor (TF) and is FDA-approved for
Aducanumab: Mechanism, Clinical Applications, and the Role of Biosimilars in Research(Post)Quick Facts About AducanumabWhat is Aducanumab?Aducanumab is a monoclonal antibody designed to target and reduce amyloid-beta plaques in the brain, a hallmark of Alzheimer’s disease.What
Glenzocimab: A Novel Antiplatelet Therapy for Stroke Prevention(Post)Quick Facts About GlenzocimabWhat is Glenzocimab?Glenzocimab is an innovative monoclonal antibody designed to reduce the risk of ischemic stroke by selectively targeting platelet glycopr
Spatial Transcriptomics: Mapping the Future of Medicine at Cellular Resolution(Post)Spatial Transcriptomics: Mapping the Future of Medicine at Cellular Resolution Imagine being able to create a detailed map of a city, not just showing the streets and buildings, but also revealing th
COVID-19에서의 항체 반응: SARS-COV-2 진단 테스트에서의 혈청 전환 영향(Post)주요 포인트: COVID-19,SARS-COV-2에의한 유행성 코로나 바이러스 질환은 예비 데이터에 따르면, 전형적인 혈청 전환 및 면역 글로불린 클래스 (이소형) 전환 시간 과정을 따르는 것으로 나타났다. 증상 발병 2 주 후 임상 중증도와 항
Praluzatamab: Unveiling the Promise of CD47-Targeted Therapy in Cancer Research(Post)Quick Facts About PraluzatamabWhat is Praluzatamab?Praluzatamab is an experimental monoclonal antibody that targets CD47, a “don’t eat me” signal used by cancer cells to evade immune des
Anti-PD-1: Restoring T Cell Function in Cancer Immunotherapy(Post)Cancer immunotherapy has revolutionized the treatment landscape for various malignancies. One of the most promising therapeutic strategies is the use of immune checkpoint inhibitors, part
CD122: Fine-Tuning T Cell Responses in Immunotherapy(Post)Introduction to CD122 in Immunotherapy CD122, also known as the interleukin-2 receptor beta chain (IL-2Rβ), is a critical component of the immune system's response to pathogens and malign
Polatuzumab: Redefining Targeted Therapies in B-Cell Lymphoma(Post)What You Need to Know About PolatuzumabWhat is Polatuzumab??Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b, a component of the B-cell receptor, used primarily in B-cel
Prevention and Risk Mitigation: Strategies to Reduce Hantavirus Exposure in a Changing World(Post)As hantavirus cases continue to rise globally, the question becomes not just how to detect infections, but how to prevent them in the first place. Recent epidemiological investigations across Califor
Custom Assay Entwicklung: Wann sich der Aufwand wirklich lohnt(Post)Custom Assay Entwicklung: Wann sich der Aufwand wirklich lohnt Ein kundenspezifischer Assay ist dann angezeigt, wenn Standardmethoden die In-vivo-Relevanz, Matrixeffekte oder die Messbarkeit neuartig
세포 용해를위한 소니케이션(초음파 처리 분해) 프로토콜 (Page) Unlocking the Potential of Anti-CD47 in Cancer Immunotherapy(Post)Quick Facts About RagifilimabWhat is Ragifilimab?Ragifilimab is an investigational anti-CD47 monoclonal antibody developed to block the CD47-SIRPα interaction, thereby enhancing macropha
Secukinumab: A Comprehensive Guide to Its Mechanism, Applications, and Biosimilar Advancements(Post)Quick Facts About SecukinumabWhat is SecukinumabSecukinumab is a monoclonal antibody that targets interleukin-17A (IL-17A), a key cytokine involved in inflammatory and autoimmune respons
Farletuzumab: Advancing Antibody-Drug Conjugate Research in Ovarian Cancer(Post)Quick Facts About FarletuzumabWhat is Farletuzumab?Farletuzumab is a humanized monoclonal antibody targeting folate receptor alpha (FRα), a protein overexpressed in ovarian and other epi
Metabolism or pluripotency – which regulates which? A chicken or the egg story.(Post)By Sophie Arthur How many diseases and conditions do you think exist in this world? Thousands? Hundreds of thousands? Maybe even millions? Unfortunately, I don’t know the answer. But what I
PD-1 & PD-L1 Inhibitors(Post)PD-1 & PD-L1 interaction between T-cells and tumour cells. What are PD-1 and PD-L1? PD-1, also known as programmed cell death 1, is a receptor expressed on t
Tiragolumab: Unlocking New Horizons in Cancer Immunotherapy(Post)Quick Facts About TiragolumabWhat is Tiragolumab?Tiragolumab is an anti-TIGIT monoclonal antibody developed to enhance immune responses against cancer cells. It is currently under invest
Rosopatamab: Unveiling the Potential of Anti-CD47 Therapy in Cancer Research(Post)Quick Facts About RosopatamabWhat is Rosopatamab?Rosopatamab is a monoclonal antibody targeting CD47, a critical immune checkpoint that helps cancer cells evade immune detection. By bloc